For many years, the laboratory investigation of patients with thrombophilia has lagged behind that of patients with bleeding diathesis, Improved understanding of the mechanisms that control and regulate coagulation, and the resultant recognition of new defects, have greatly stimulated clinical laboratory interest in this area. Assays to detect resistance to activated protein C; deficiencies of antithrombin, protein C, and protein S; and the presence of antiphospholipid antibodies are widely available and should form part of the investigation of patients that present with idiopathic thrombosis, Such a work-up will likely provide an explanation for thrombosis in 40 to 60 % of patients. Abnormalities of fibrinogen and fibrinolysis may explain still more, although such defects are currently considered rare, In addition, presently unrecognized defects almost certainly exist, and the identification of such individuals will undoubtedly improve our understanding of the hemostatic mechanism, Laboratory tests to define the hypercoagulable state are continually being developed, They include whole blood coagulation and platelet function tests and novel activation markers. However, acceptance of these approaches by clinical laboratories has been slow.